Drug Shortage Report for AA-RISEDRONATE DR
Report ID | 156999 |
Drug Identification Number | 02493268 |
Brand name | APO-RISEDRONATE DR |
Common or Proper name | RISEDRONATE |
Company Name | AA PHARMA INC |
Market Status | MARKETED |
Active Ingredient(s) | RISEDRONATE SODIUM |
Strength(s) | 35MG |
Dosage form(s) | TABLET (DELAYED-RELEASE) |
Route of administration | ORAL |
Packaging size | 4 BLS |
ATC code | M05BA |
ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-03-15 |
Estimated end date | 2022-04-08 |
Actual end date | 2022-04-05 |
Shortage status | Resolved |
Updated date | 2022-04-06 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1165 CREDITSTONE ROAD VAUGHAN, ONTARIO CANADA L4K 4N7 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-04-06 | French | Compare |
v5 | 2022-04-06 | English | Compare |
v4 | 2022-04-01 | French | Compare |
v3 | 2022-04-01 | English | Compare |
v2 | 2022-03-18 | French | Compare |
v1 | 2022-03-18 | English | Compare |
Showing 1 to 6 of 6